Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study
that will evaluate the clinical efficacy, safety and tolerability of increasing doses of
XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy,
followed by an optional open-label extension (OLE).
Phase
Phase 2
Funding Agency/Sponsor
Industry
Disease
Epilepsy
Enrollment Eligibility
Key Inclusion Criteria:
- Be properly informed of the nature and risks of the study and give informed consent in
writing, prior to entering the study
- BMI ≤40 kg/m2
- Diagnosis (≥2 years) of focal epilepsy according to the International League Against
Epilepsy [ILAE] Classification of Epilepsy (2017)
- Prior neuroimaging within the last 10 years and documentation is available
- Treatment with a stable dose of 1 to 3 allowable current AEDs for at least one month
prior to screening, during baseline, and throughout the duration of the DBP
- Must be willing to comply with the contraception requirements
- Males must agree not to donate sperm from the time of the first administration of
study drug until 6 months after the last dose. Females must agree not to donate ova
from the time of the first administration of study drug until 6 months after the last
dose.
- Able to keep accurate seizure diaries
Key Exclusion Criteria:
- History of pseudoseizures, psychogenic seizures, primary generalized seizure, or focal
aware non-motor seizures only
- Presence or previous history of Lennox-Gastaut syndrome
- Seizures secondary to other diseases or conditions
- History of repetitive seizures within the last 12 months where the individual seizures
cannot be counted
- History of neurosurgery for seizures <1 year prior to enrollment, or radiosurgery <2
years prior to enrollment
- Schizophrenia and other psychotic disorders, or active suicidal plan/intent in the
past 6 months, or a history of suicide attempt in the last 2 years, or more than 1
lifetime suicide attempt
- History or presence of any significant medical or surgical condition or uncontrolled
medical illness at screening, or history of cancer within the past 2 years, with the
exception of appropriately treated basal cell or squamous cell carcinoma
- Any clinically significant abnormalities on pre-study physical examination, vital
signs, laboratory values or ECG indicating a medical problem that would preclude study
participation including but not limited to:
1. History of presence of long QT syndrome; QTcF > 450 msec at baseline; family
history of sudden death of unknown cause
2. History of skin or retinal pigment epithelium abnormalities caused by ezogabine
- Past use of vigabatrin without stable visual fields tested twice over the 12 months
after the last dose of vigabatrin (concomitant use of vigabatrin is not allowed)
- If felbamate is used as a concomitant AED, patients must be taking it for at least 2
years, with a stable dose for 2 months (or no less than 49 days) and acceptable
hematology and LFT history and values prior to Screening. If received in the past,
felbamate must have been discontinued 2 months (or no less than 49 days) prior to
Screening.
- Have had multiple drug allergies or a severe drug reaction to an AED(s), including
dermatological (e.g., Stevens-Johnson syndrome), hematological, or organ toxicity
reactions
- Current use of a ketogenic diet